Warts - Pipeline Review, H2 2018

Publisher Name :
Date: 17-Jul-2018
No. of pages: 100
Inquire Before Buying

Warts - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2018, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 17, 2, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Warts - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Warts - Overview
Warts - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Warts - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Warts - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Agilvax Inc
BioMAS Ltd
Cadila Healthcare Ltd
Cutanea Life Sciences Inc
Cytovation AS
G&E Corp
Genetic Immunity Inc
Laboratories Ojer Pharma SL
LEO Pharma A/S
Maruho Co Ltd
Nielsen Biosciences Inc
Novan Inc
Novartis AG
Pfizer Inc
Promius Pharma LLC
RXi Pharmaceuticals Corp
Tamir Biotechnology Inc
Vaxart Inc
Verrica Pharmaceuticals Inc
Warts - Drug Profiles
(digoxin + furosemide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Albicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AX-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Condyloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyPep-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFD-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FIT-039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
furosemide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HupaDerm - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrogen peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ingenol mebutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LFX-453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pefcalcitol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
povidone iodine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranpirnase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RKP-00156 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Samcyprone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teslexivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Warts - Dormant Projects
Warts - Discontinued Products
Warts - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir for the Treatment of Condyloma
May 18, 2018: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone for the Treatment of Common Warts
Apr 04, 2018: RXi Pharmaceuticals to Present on Samcyprone at the International Investigative Dermatology Conference
Mar 19, 2018: Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts
Jan 08, 2018: Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts
Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
Sep 06, 2017: RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
Jun 29, 2017: Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts
Apr 26, 2017: Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution
Mar 02, 2017: Novan's Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting
Mar 01, 2017: Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference
Nov 29, 2016: Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206
Aug 18, 2016: Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
Jul 30, 2016: Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts
Jul 21, 2016: RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Warts, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Warts - Pipeline by Aclaris Therapeutics Inc, H2 2018
Warts - Pipeline by Agilvax Inc, H2 2018
Warts - Pipeline by BioMAS Ltd, H2 2018
Warts - Pipeline by Cadila Healthcare Ltd, H2 2018
Warts - Pipeline by Cutanea Life Sciences Inc, H2 2018
Warts - Pipeline by Cytovation AS, H2 2018
Warts - Pipeline by G&E Corp, H2 2018
Warts - Pipeline by Genetic Immunity Inc, H2 2018
Warts - Pipeline by Laboratories Ojer Pharma SL, H2 2018
Warts - Pipeline by LEO Pharma A/S, H2 2018
Warts - Pipeline by Maruho Co Ltd, H2 2018
Warts - Pipeline by Nielsen Biosciences Inc, H2 2018
Warts - Pipeline by Novan Inc, H2 2018
Warts - Pipeline by Novartis AG, H2 2018
Warts - Pipeline by Pfizer Inc, H2 2018
Warts - Pipeline by Promius Pharma LLC, H2 2018
Warts - Pipeline by RXi Pharmaceuticals Corp, H2 2018
Warts - Pipeline by Tamir Biotechnology Inc, H2 2018
Warts - Pipeline by Vaxart Inc, H2 2018
Warts - Pipeline by Verrica Pharmaceuticals Inc, H2 2018
Warts - Dormant Projects, H2 2018
Warts - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Warts, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Cephalosporin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 109
    Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections. Cephalosporin originally derived from The fungus Acremonium, which was previously known as "Cephalosporium". The global Cephalosporin market was valued at US$ 1380.7 million in 2023 and is anticipated to reach US$ 1346.9 million by 2030, witnessing a CAGR of -0.3% during The forecast period 2024-2030. Market competition is intense. Qilu Antibiotics, Nectar Lifes......
  • Global Polymixin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 120
    According to our LPI (LP Information) latest study, the global Polymixin market size was valued at US$ 229.9 million in 2023. With growing demand in downstream market, the Polymixin is forecast to a readjusted size of US$ 291 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Polymixin market. Polymixin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and sup......
  • Global Sepsis Partnering Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The Sepsis Partnering market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sepsis Partnering market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape......
  • Global Cephalosporin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 156
    According to our LPI (LP Information) latest study, the global Cephalosporin market size was valued at US$ 1350.7 million in 2023. With growing demand in downstream market, the Cephalosporin is forecast to a readjusted size of US$ 1319.6 million by 2030 with a CAGR of -0.3% during review period. The research report highlights the growth potential of the global Cephalosporin market. Cephalosporin are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Amoxicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 127
    According to our LPI (LP Information) latest study, the global Amoxicillin market size was valued at US$ 4512.7 million in 2023. With growing demand in downstream market, the Amoxicillin is forecast to a readjusted size of US$ 5711.7 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Amoxicillin market. Amoxicillin are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Metronidazole Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 136
    According to our LPI (LP Information) latest study, the global Metronidazole market size was valued at US$ 110.5 million in 2023. With growing demand in downstream market, the Metronidazole is forecast to a readjusted size of US$ 106.6 million by 2030 with a CAGR of -0.5% during review period. The research report highlights the growth potential of the global Metronidazole market. Metronidazole are expected to show stable growth in the future market. However, product differentiation, redu......
  • Global Drugs for Herpes Labialis (Oral Herpes) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Drugs for Herpes Labialis (Oral Herpes) market size was valued at US$ 2404.5 million in 2023. With growing demand in downstream market, the Drugs for Herpes Labialis (Oral Herpes) is forecast to a readjusted size of US$ 3402.2 million by 2030 with a CAGR of 5.1% during review period. The research report highlights the growth potential of the global Drugs for Herpes Labialis (Oral Herpes) market. Drugs for Herpes Labialis (Ora......
  • Global Ampicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Ampicillin market size was valued at US$ 161.6 million in 2023. With growing demand in downstream market, the Ampicillin is forecast to a readjusted size of US$ 194.7 million by 2030 with a CAGR of 2.7% during review period. The research report highlights the growth potential of the global Ampicillin market. Ampicillin are expected to show stable growth in the future market. However, product differentiation, reducing costs, a......
  • Global Acinetobacter Infections Treatment Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101
    According to our LPI (LP Information) latest study, the global Acinetobacter Infections Treatment market size was valued at US$ million in 2023. With growing demand in downstream market, the Acinetobacter Infections Treatment is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Acinetobacter Infections Treatment market. Acinetobacter Infections Treatment are expected to show stable ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs